Monoclonal antibody | |
---|---|
Type | Whole antibody |
Target | Factor XI and its active form Factor XIa |
Clinical data | |
Other names | MAA868 |
AHFS/Drugs.com | Monograph |
License data |
|
Routes of administration | Intravenous |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
KEGG |
Abelacimab (MAA868), is a fully human monoclonal antibody for the treatment of coagulation,[1] under development by Anthos Therapeutics.
YouTube Encyclopedic
-
1/5Views:8824054 2211 721487
-
Abelacimab for prevention of venous thromboembolism. NEJM 2021
-
AVATAR Trial. Aortic valve surgery in Asymptomatic Severe Aortic Stenosis. AHA-2021
-
Przyszłość w leczeniu migotania–wziewne leki antyarytmiczne,nowe leki przeciwkrzepliwe,ablacja,inne
-
FAME 3 Trial. FFR guided PCI Vs CABG in three vessel CAD
-
Revascularization in Stable Coronary Artery Disease. Lessons from ISCHEMIA, COURAGE, FREEDOM, ORBITA
Transcription
Mechanism of action
It is anti-factor XI antibody.[1][2]
See also
References
- ^ a b Verhamme P, Yi BA, Segers A, Salter J, Bloomfield D, Büller HR, et al. (August 2021). "Abelacimab for Prevention of Venous Thromboembolism". The New England Journal of Medicine. 385 (7): 609–617. doi:10.1056/NEJMoa2105872. PMID 34297496. S2CID 236198598.
- ^ "Atrial Fibrillation Study with Abelacimab Stopped Early by the Data Monitoring Committee Due to an Overwhelming Reduction in Bleeding as Compared to a DOAC (Direct Oral Anticoagulant)". Business Wire. 18 September 2023.
This page was last edited on 9 March 2024, at 08:53